Now showing items 1-20 of 33

    • A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. 

      Glasspool, RM; Brown, R; Gore, ME; Rustin, GJS; McNeish, IA; Wilson, RH; Pledge, S; Paul, J; Mackean, M; Hall, GD; Gabra, H; Halford, SER; Walker, J; Appleton, K; Ullah, R; Kaye, S; Scottish Gynaecological Trials Group (2014-04)
      Background Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis ...
    • A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. 

      Del Campo, JM; Birrer, M; Davis, C; Fujiwara, K; Gollerkeri, A; Gore, M; Houk, B; Lau, S; Poveda, A; González-Martín, A; Muller, C; Muro, K; Pierce, K; Suzuki, M; Vermette, J; Oza, A (2016-07)
      Objective PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II study (B1271004) was conducted in patients with recurrent endometrial cancer following platinum-containing chemotherapy. ...
    • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 

      Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, CG; Marples, M; Danson, SJ; Marshall, E; Houston, SJ; Board, RE; Waterston, AM; Nobes, JP; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, PM; Ottensmeier, CH; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, EO; Harman, C; Weiss, M; Myers, KA; Chhabra, A; Rodwell, SH; Dunn, JA; Middleton, MR; AVAST-M Investigators; Nathan, P; Lorigan, P; Dziewulski, P; Holikova, S; Panwar, U; Tahir, S; Faust, G; Thomas, A; Corrie, P; Sirohi, B; Kelly, C; Middleton, M; Marples, M; Danson, S; Lester, J; Marshall, E; Ajaz, M; Houston, S; Board, R; Eaton, D; Waterston, A; Nobes, J; Loo, S; Gray, G; Stubbings, H; Gore, M; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Marsden, J; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Marshall, E; Patel, P; Ottensmeier, C; Farrugia, D; Humphreys, A; Eccles, B; Dega, R; Herbert, C; Price, C; Brunt, M; Scott-Brown, M; Hamilton, J; Hayward, RL; Smyth, J; Woodings, P; Nayak, N; Burrows, L; Wolstenholme, V; Wagstaff, J; Nicolson, M; Wilson, A; Barlow, C; Scrase, C; Podd, T; Gonzalez, M; Stewart, J; Highley, M; Wolstenholme, V; Grumett, S; Goodman, A; Talbot, T; Nathan, K; Coltart, R; Gee, B; Gore, M; Farrugia, D; Martin-Clavijo, A; Marsden, J; Price, C; Farrugia, D; Nathan, K; Coltart, R; Nathan, K; Coltart, R (2018-08)
      Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ...
    • Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. 

      Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; Rye, T; Chen, L-M; Shapira-Frommer, R; Friedlander, M; Matulonis, U; De Greve, J; Oza, AM; Banerjee, S; Molife, LR; Gore, ME; Kaye, SB; Yap, TA (2017-07)
      Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ...
    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. 

      George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)
      Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
    • Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. 

      Lim, KHJ; Spain, L; Barker, C; Georgiou, A; Walls, G; Gore, M; Turajlic, S; Board, R; Larkin, JM; Lorigan, P (2018-01)
      Background:Agreement on the utility of imaging follow-up in patients with high-risk melanoma is lacking. A UK consensus statement recommends a surveillance schedule of CT or positron-emission tomography-CT and MRI brain ...
    • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-12)
      The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
    • Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. 

      Fisher, R; Horswell, S; Rowan, A; Salm, MP; de Bruin, EC; Gulati, S; McGranahan, N; Stares, M; Gerlinger, M; Varela, I; Crockford, A; Favero, F; Quidville, V; André, F; Navas, C; Grönroos, E; Nicol, D; Hazell, S; Hrouda, D; O'Brien, T; Matthews, N; Phillimore, B; Begum, S; Rabinowitz, A; Biggs, J; Bates, PA; McDonald, NQ; Stamp, G; Spencer-Dene, B; Hsieh, JJ; Xu, J; Pickering, L; Gore, M; Larkin, J; Swanton, C (2014-08-27)
      Background Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.Results We perform whole exome sequencing on four clear ...
    • Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. 

      Spain, L; Walls, G; Messiou, C; Turajlic, S; Gore, M; Larkin, J (2017-01)
      Background The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant ...
    • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. 

      Arce Vargas, F; Furness, AJS; Litchfield, K; Joshi, K; Rosenthal, R; Ghorani, E; Solomon, I; Lesko, MH; Ruef, N; Roddie, C; Henry, JY; Spain, L; Ben Aissa, A; Georgiou, A; Wong, YNS; Smith, M; Strauss, D; Hayes, A; Nicol, D; O'Brien, T; Mårtensson, L; Ljungars, A; Teige, I; Frendéus, B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia; Pule, M; Marafioti, T; Gore, M; Larkin, J; Turajlic, S; Swanton, C; Peggs, KS; Quezada, SA (2018-04)
      With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion ...
    • Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. 

      Arce Vargas, F; Furness, AJS; Solomon, I; Joshi, K; Mekkaoui, L; Lesko, MH; Miranda Rota, E; Dahan, R; Georgiou, A; Sledzinska, A; Ben Aissa, A; Franz, D; Werner Sunderland, M; Wong, YNS; Henry, JY; O'Brien, T; Nicol, D; Challacombe, B; Beers, SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic, S; Gore, M; Larkin, J; Swanton, C; Chester, KA; Pule, M; Ravetch, JV; Marafioti, T; Peggs, KS; Quezada, SA (2017-04-11)
      CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We ...
    • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 

      Phelan, CM; Kuchenbaecker, KB; Tyrer, JP; Kar, SP; Lawrenson, K; Winham, SJ; Dennis, J; Pirie, A; Riggan, MJ; Chornokur, G; Earp, MA; Lyra, PC; Lee, JM; Coetzee, S; Beesley, J; McGuffog, L; Soucy, P; Dicks, E; Lee, A; Barrowdale, D; Lecarpentier, J; Leslie, G; Aalfs, CM; Aben, KKH; Adams, M; Adlard, J; Andrulis, IL; Anton-Culver, H; Antonenkova, N; AOCS study group; Aravantinos, G; Arnold, N; Arun, BK; Arver, B; Azzollini, J; Balmaña, J; Banerjee, SN; Barjhoux, L; Barkardottir, RB; Bean, Y; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Bernardini, MQ; Birrer, MJ; Bjorge, L; Black, A; Blankstein, K; Blok, MJ; Bodelon, C; Bogdanova, N; Bojesen, A; Bonanni, B; Borg, Å; Bradbury, AR; Brenton, JD; Brewer, C; Brinton, L; Broberg, P; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Buecher, B; Butzow, R; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Cannioto, R; Carney, ME; Cescon, T; Chan, SB; Chang-Claude, J; Chanock, S; Chen, XQ; Chiew, Y-E; Chiquette, J; Chung, WK; Claes, KBM; Conner, T; Cook, LS; Cook, J; Cramer, DW; Cunningham, JM; D'Aloisio, AA; Daly, MB; Damiola, F; Damirovna, SD; Dansonka-Mieszkowska, A; Dao, F; Davidson, R; DeFazio, A; Delnatte, C; Doheny, KF; Diez, O; Ding, YC; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Dossus, L; Duran, M; Dürst, M; Dworniczak, B; Eccles, D; Edwards, T; Eeles, R; Eilber, U; Ejlertsen, B; Ekici, AB; Ellis, S; Elvira, M; EMBRACE Study; Eng, KH; Engel, C; Evans, DG; Fasching, PA; Ferguson, S; Ferrer, SF; Flanagan, JM; Fogarty, ZC; Fortner, RT; Fostira, F; Foulkes, WD; Fountzilas, G; Fridley, BL; Friebel, TM; Friedman, E; Frost, D; Ganz, PA; Garber, J; García, MJ; Garcia-Barberan, V; Gehrig, A; GEMO Study Collaborators; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goldgar, DE; Goranova, T; Gore, M; Greene, MH; Gronwald, J; Gruber, S; Hahnen, E; Haiman, CA; Håkansson, N; Hamann, U; Hansen, TVO; Harrington, PA; Harris, HR; Hauke, J; HEBON Study; Hein, A; Henderson, A; Hildebrandt, MAT; Hillemanns, P; Hodgson, S; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Holland, H; Hooning, MJ; Hosking, K; Huang, R-Y; Hulick, PJ; Hung, J; Hunter, DJ; Huntsman, DG; Huzarski, T; Imyanitov, EN; Isaacs, C; Iversen, ES; Izatt, L; Izquierdo, A; Jakubowska, A; James, P; Janavicius, R; Jernetz, M; Jensen, A; Jensen, UB; John, EM; Johnatty, S; Jones, ME; Kannisto, P; Karlan, BY; Karnezis, A; Kast, K; KConFab Investigators; Kennedy, CJ; Khusnutdinova, E; Kiemeney, LA; Kiiski, JI; Kim, S-W; Kjaer, SK; Köbel, M; Kopperud, RK; Kruse, TA; Kupryjanczyk, J; Kwong, A; Laitman, Y; Lambrechts, D; Larrañaga, N; Larson, MC; Lazaro, C; Le, ND; Le Marchand, L; Lee, JW; Lele, SB; Leminen, A; Leroux, D; Lester, J; Lesueur, F; Levine, DA; Liang, D; Liebrich, C; Lilyquist, J; Lipworth, L; Lissowska, J; Lu, KH; Lubinński, J; Luccarini, C; Lundvall, L; Mai, PL; Mendoza-Fandiño, G; Manoukian, S; Massuger, LFAG; May, T; Mazoyer, S; McAlpine, JN; McGuire, V; McLaughlin, JR; McNeish, I; Meijers-Heijboer, H; Meindl, A; Menon, U; Mensenkamp, AR; Merritt, MA; Milne, RL; Mitchell, G; Modugno, F; Moes-Sosnowska, J; Moffitt, M; Montagna, M; Moysich, KB; Mulligan, AM; Musinsky, J; Nathanson, KL; Nedergaard, L; Ness, RB; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nussbaum, RL; Odunsi, K; Olah, E; Olopade, OI; Olsson, H; Olswold, C; O'Malley, DM; Ong, K-R; Onland-Moret, NC; OPAL study group; Orr, N; Orsulic, S; Osorio, A; Palli, D; Papi, L; Park-Simon, T-W; Paul, J; Pearce, CL; Pedersen, IS; Peeters, PHM; Peissel, B; Peixoto, A; Pejovic, T; Pelttari, LM; Permuth, JB; Peterlongo, P; Pezzani, L; Pfeiler, G; Phillips, K-A; Piedmonte, M; Pike, MC; Piskorz, AM; Poblete, SR; Pocza, T; Poole, EM; Poppe, B; Porteous, ME; Prieur, F; Prokofyeva, D; Pugh, E; Pujana, MA; Pujol, P; Radice, P; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Rhiem, K; Rice, P; Richardson, A; Robson, M; Rodriguez, GC; Rodríguez-Antona, C; Romm, J; Rookus, MA; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, IB; Salvesen, HB; Sandler, DP; Schoemaker, MJ; Senter, L; Setiawan, VW; Severi, G; Sharma, P; Shelford, T; Siddiqui, N; Side, LE; Sieh, W; Singer, CF; Sobol, H; Song, H; Southey, MC; Spurdle, AB; Stadler, Z; Steinemann, D; Stoppa-Lyonnet, D; Sucheston-Campbell, LE; Sukiennicki, G; Sutphen, R; Sutter, C; Swerdlow, AJ; Szabo, CI; Szafron, L; Tan, YY; Taylor, JA; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, KL; Thompson, PJ; Thomsen, LCV; Thull, DL; Tihomirova, L; Tinker, AV; Tischkowitz, M; Tognazzo, S; Toland, AE; Tone, A; Trabert, B; Travis, RC; Trichopoulou, A; Tung, N; Tworoger, SS; van Altena, AM; Van Den Berg, D; van der Hout, AH; van der Luijt, RB; Van Heetvelde, M; Van Nieuwenhuysen, E; van Rensburg, EJ; Vanderstichele, A; Varon-Mateeva, R; Vega, A; Edwards, DV; Vergote, I; Vierkant, RA; Vijai, J; Vratimos, A; Walker, L; Walsh, C; Wand, D; Wang-Gohrke, S; Wappenschmidt, B; Webb, PM; Weinberg, CR; Weitzel, JN; Wentzensen, N; Whittemore, AS; Wijnen, JT; Wilkens, LR; Wolk, A; Woo, M; Wu, X; Wu, AH; Yang, H; Yannoukakos, D; Ziogas, A; Zorn, KK; Narod, SA; Easton, DF; Amos, CI; Schildkraut, JM; Ramus, SJ; Ottini, L; Goodman, MT; Park, SK; Kelemen, LE; Risch, HA; Thomassen, M; Offit, K; Simard, J; Schmutzler, RK; Hazelett, D; Monteiro, AN; Couch, FJ; Berchuck, A; Chenevix-Trench, G; Goode, EL; Sellers, TA; Gayther, SA; Antoniou, AC; Pharoah, PDP (2017-05)
      To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified ...
    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. 

      George, A; Riddell, D; Seal, S; Talukdar, S; Mahamdallie, S; Ruark, E; Cloke, V; Slade, I; Kemp, Z; Gore, M; Strydom, A; Banerjee, S; Hanson, H; Rahman, N (2016-07-13)
      Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing ...
    • Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. 

      Turajlic, S; Litchfield, K; Xu, H; Rosenthal, R; McGranahan, N; Reading, JL; Wong, YNS; Rowan, A; Kanu, N; Al Bakir, M; Chambers, T; Salgado, R; Savas, P; Loi, S; Birkbak, NJ; Sansregret, L; Gore, M; Larkin, J; Quezada, SA; Swanton, C (2017-08)
      Background The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the ...
    • Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. 

      Tannir, NM; Figlin, RA; Gore, ME; Michaelson, MD; Motzer, RJ; Porta, C; Rini, BI; Hoang, C; Lin, X; Escudier, B (2017-06-20)
      Background We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) ...
    • Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. 

      Spain, L; Walls, G; Julve, M; O'Meara, K; Schmid, T; Kalaitzaki, E; Turajlic, S; Gore, M; Rees, J; Larkin, J (2017-02)
      Background Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase ...
    • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

      Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Australian Ovarian Cancer Study Group; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Breast Cancer Family Register; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KBM; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IDS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; EMBRACE; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; GEMO Study Collaborators; GENICA Network; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TVO; Harter, P; Hartikainen, JM; Healey, S; HEBON; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; KConFab Investigators; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, V-M; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JWM; Massuger, LFAG; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, K-A; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MWR; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; SWE-BRCA; Swerdlow, A; Tangen, IL; Tea, M-K; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AMW; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PDP; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
      Objective Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer ...
    • Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. 

      Oza, A; Kaye, S; Van Tornout, J; Sessa, C; Gore, M; Naumann, RW; Hirte, H; Colombo, N; Chen, J; Gorla, S; Poondru, S; Singh, M; Steinberg, J; Yuen, G; Banerjee, S (2018-05)
      BACKGROUND:Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients ...